Cerebrovascular Accident in a High-Risk Patient During the Early Initiation Phase With Canagliflozin

Annals of Pharmacotherapy

Volumn 48, Issue 8, 2014, Pages 1066-1069

  Foushee, Jaime A ^a,b   Goodbar, Nancy H ^a,b   Kelly, Jason L ^b   Clarke, L Lindsey ^b  

^a PRESBYTERIAN COLLEGE   (United States)

^b Self Regional Healthcare   (United States)

Author keywords

adverse drug reaction; diabetes mellitus type 2; drug safety; medication safety; stroke

Indexed keywords

ACETYLSALICYLIC ACID; CANAGLIFLOZIN; INSULIN DETEMIR; LEVOTHYROXINE; LISINOPRIL; METFORMIN; PRAVASTATIN; SALBUTAMOL;

ADULT; ARTICLE; ATAXIC APHASIA; BASAL GANGLION; BRAIN INFARCTION; CASE REPORT; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; MIDDLE AGED; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; SPEECH THERAPY; TEMPORAL LOBE;

EID: 84904507770     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014529412     Document Type: Article

References (14)

1. Invokana (canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2013:.
2. Stenlöf K,Cefalu WT,Kim KA,et al.Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Diabetes Obes Metab. 2013;15:372-382.
3. Cefalu WT,Leiter LA,Yoon KH,et al.Efficacy and safety of canagliflozin versus glimiperide in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.Lancet. 2013;382:941-950.
4. Schernthaner G,Gross JL,Rosenstock J,et al.Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.Diabetes Care. 2013;36:2508-2515.
5. Devineni D,Morrow L,Hompesch M,et al.Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.Diabetes Obes Metab. 2012;14:539-545.
6. Rosenstock J,Aggarwal N,Polidori D,et al.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.Diabetes Care. 2012;35:1232-1238.
7. Food and Drug Administration. FDA Briefing Document NDA 204042: Invokana (canagliflozin) tablets. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Accessed August 21, 2013.
8. Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med. 2007;356:2457-2471.
9. Standards of medical care in diabetes: 2013.Diabetes Care. 2013;36:S11-S66.
10. Garber AJ,Abrahamson MJ,Barzilay JI,et al.American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement: executive summary.Endocr Pract. 2013;19:536-557.
11. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes.Lancet. 1998;352:854-865.
12. Singh S,Loke YK,Furberg CD.Long term risk of cardiovascular events with rosiglitazone: a meta-analysis.JAMA. 2007;298:1189-1195.
13. Neal B,Perkovic V,de Zeeuw D,et al.Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS): a randomized placebo-controlled trial.Am Heart J. 2013;166:217-223.e11.
14. Naranjo CA,Busto U,Sellers EM,et al.A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther. 1981;30:239-245.